A Comparison of Clinical Characteristics of Infections with SARS-CoV-2 Omicron Subvariants BF.7.14 and BA.5.2.48 - China, October-December 2022.

China CDC Weekly Pub Date : 2023-06-09 DOI:10.46234/ccdcw2023.096

Da Huo, Tong Yu, Ying Shen, Yang Pan, Fu Li, Shujuan Cui, Bing Lyu, Zhichao Liang, Daitao Zhang, Peng Yang, Quanyi Wang, Yue Sun, Zhaomin Feng

{"title":"A Comparison of Clinical Characteristics of Infections with SARS-CoV-2 Omicron Subvariants BF.7.14 and BA.5.2.48 - China, October-December 2022.","authors":"Da Huo, Tong Yu, Ying Shen, Yang Pan, Fu Li, Shujuan Cui, Bing Lyu, Zhichao Liang, Daitao Zhang, Peng Yang, Quanyi Wang, Yue Sun, Zhaomin Feng","doi":"10.46234/ccdcw2023.096","DOIUrl":null,"url":null,"abstract":"What is already known about this topic?: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, the clinical manifestations resulting from different SARS-CoV-2 variants may demonstrate significant variation.What is added by this report?: We conducted a comparative analysis of the clinical features associated with SARS-CoV-2 Omicron subvariants BF.7.14 and BA.5.2.48 infections. The results of our study indicate that there are no substantial differences in clinical manifestations, duration of illness, healthcare-seeking behaviors, or treatment between these two subvariants.What are the implications for public health practice?: Timely identification of alterations in the clinical spectrum is crucial for researchers and healthcare practitioners in order to enhance their comprehension of clinical manifestations, as well as the progression of SARS-CoV-2. Furthermore, this information is beneficial for policymakers in the process of revising and implementing appropriate countermeasures.","PeriodicalId":9867,"journal":{"name":"China CDC Weekly","volume":"5 23","pages":"511-515"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/fa/ccdcw-5-23-511.PMC10316608.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"China CDC Weekly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46234/ccdcw2023.096","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

What is already known about this topic?: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, the clinical manifestations resulting from different SARS-CoV-2 variants may demonstrate significant variation.

What is added by this report?: We conducted a comparative analysis of the clinical features associated with SARS-CoV-2 Omicron subvariants BF.7.14 and BA.5.2.48 infections. The results of our study indicate that there are no substantial differences in clinical manifestations, duration of illness, healthcare-seeking behaviors, or treatment between these two subvariants.

What are the implications for public health practice?: Timely identification of alterations in the clinical spectrum is crucial for researchers and healthcare practitioners in order to enhance their comprehension of clinical manifestations, as well as the progression of SARS-CoV-2. Furthermore, this information is beneficial for policymakers in the process of revising and implementing appropriate countermeasures.

查看原文本刊更多论文

SARS-CoV-2组粒亚变体BF.7.14和BA.5.2.48感染的临床特征比较——中国，2022年10 - 12月

关于这个话题我们已经知道了什么?严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)持续进化，不同SARS-CoV-2变异引起的临床表现可能存在显著差异。这份报告增加了什么内容?我们对SARS-CoV-2 Omicron亚型BF.7.14和BA.5.2.48感染的临床特征进行了比较分析。我们的研究结果表明，在临床表现、病程、就医行为或治疗方面，这两个亚变体之间没有实质性的差异。这对公共卫生实践有什么影响?及时识别临床谱的变化对研究人员和医疗从业人员来说至关重要，以增强他们对临床表现和SARS-CoV-2进展的理解。此外，这些信息有助于决策者在修改和实施适当的对策的过程中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

China CDC Weekly

自引率

0.00%

发文量